Background: Prostate cancer (PC), a malignant tumor occurring in the male prostate tissue, has a high incidence rate. In this study, we explored the role of tripartite motif 47 (TRIM47) in the progression of PC and its underlying mechanism.
Methods: PC and paracancerous tissues were collected from Shenzhen Peoples's Hospital. The following methods were employed in this experiment: quantitative polymerase chain reaction (qPCR), immunofluorescent staining, cell counting kit-8 (CCK-8), ethynyl deoxyuridine (EdU), and Western blot.
Results: The expression levels of TRIM47 were up-regulated in patients with PC. TRIM47 was found to promote cell growth and induce the Warburg effect, while also reducing ferroptosis in PC cells. Conversely, the knockdown of TRIM47 [small interfering RNA, (si)-TRIM47] decreased cell growth and the Warburg effect, while promoting ferroptosis in PC cells. Additionally, TRIM47 was observed to induce the protein expression levels of fructose-1,6-bisphosphatase 1 (FBP1) and forkhead box protein O1 (FOXO1) in PC cells. Further, TRIM47 protein was found to interact with both the FBP1 and FOXO1 proteins in the PC cells. The inhibition of FBP1 attenuated the effects of TRIM47 on the Warburg effect in PC cells, while the inhibition of FOXO1 diminished the effects of TRIM47 on ferroptosis in PC cells.
Conclusions: Our findings suggest that TRIM47 promotes the Warburg effect of PC by inducing FBP1 and FOXO1. Thus, our findings suggest that targeting TRIM47 could serve as a viable therapeutic strategy for the treatment of PC.
背景：前列腺癌（PC）是一种发生在男性前列腺组织中的恶性肿瘤，发病率很高。本研究探讨了三方基序 47（TRIM47）在前列腺癌进展过程中的作用及其内在机制：方法：PC和癌旁组织取自深圳市人民医院。本实验采用了以下方法：定量聚合酶链反应（qPCR）、免疫荧光染色、细胞计数试剂盒-8（CCK-8）、乙炔基脱氧尿苷（EdU）、Western blot：结果：TRIM47在PC患者中的表达水平呈上调趋势。结果表明：TRIM47在PC患者中的表达水平上调，TRIM47能促进细胞生长并诱导沃伯格效应，同时还能降低PC细胞的铁突变。相反，敲除 TRIM47 [small interfering RNA, (si)-TRIM47]会降低 PC 细胞的生长和沃伯格效应，同时促进铁凋亡。此外，还观察到 TRIM47 能诱导 PC 细胞中果糖-1,6-二磷酸酶 1（FBP1）和叉头盒蛋白 O1（FOXO1）的蛋白表达水平。此外，还发现 TRIM47 蛋白与 PC 细胞中的 FBP1 和 FOXO1 蛋白相互作用。抑制FBP1可减轻TRIM47对PC细胞沃伯格效应的影响，而抑制FOXO1则可减弱TRIM47对PC细胞铁变态反应的影响：我们的研究结果表明，TRIM47通过诱导FBP1和FOXO1促进PC的沃伯格效应。因此，我们的研究结果表明，靶向 TRIM47 可作为治疗 PC 的一种可行的治疗策略。
{"title":"TRIM47 promotes the Warburg effect and reduces ferroptosis in prostate cancer by FBP1 and FOXO1.","authors":"Chubiao Zhao, Zengqin Liu, Junming Peng, Jiansheng Huang, Jinan Guo","doi":"10.21037/tau-23-605","DOIUrl":"10.21037/tau-23-605","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PC), a malignant tumor occurring in the male prostate tissue, has a high incidence rate. In this study, we explored the role of tripartite motif 47 (TRIM47) in the progression of PC and its underlying mechanism.</p><p><strong>Methods: </strong>PC and paracancerous tissues were collected from Shenzhen Peoples's Hospital. The following methods were employed in this experiment: quantitative polymerase chain reaction (qPCR), immunofluorescent staining, cell counting kit-8 (CCK-8), ethynyl deoxyuridine (EdU), and Western blot.</p><p><strong>Results: </strong>The expression levels of TRIM47 were up-regulated in patients with PC. TRIM47 was found to promote cell growth and induce the Warburg effect, while also reducing ferroptosis in PC cells. Conversely, the knockdown of TRIM47 [small interfering RNA, (si)-TRIM47] decreased cell growth and the Warburg effect, while promoting ferroptosis in PC cells. Additionally, TRIM47 was observed to induce the protein expression levels of fructose-1,6-bisphosphatase 1 (FBP1) and forkhead box protein O1 (FOXO1) in PC cells. Further, TRIM47 protein was found to interact with both the FBP1 and FOXO1 proteins in the PC cells. The inhibition of FBP1 attenuated the effects of TRIM47 on the Warburg effect in PC cells, while the inhibition of FOXO1 diminished the effects of TRIM47 on ferroptosis in PC cells.</p><p><strong>Conclusions: </strong>Our findings suggest that TRIM47 promotes the Warburg effect of PC by inducing FBP1 and FOXO1. Thus, our findings suggest that targeting TRIM47 could serve as a viable therapeutic strategy for the treatment of PC.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"1991-2004"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><strong>Background: </strong>Ferroptosis, an iron-dependent form of programmed cell death, significantly impacts cancer, yet its link to prostate cancer (PCa) prognosis remains underexplored. This study aims to develop and validate a ferroptosis-related gene signature to predict PCa prognosis and immune microenvironment differences, potentially identifying therapeutic targets.</p><p><strong>Methods: </strong>RNA-sequencing data of 478 PCa patients and corresponding clinical data were downloaded from The Cancer Genome Atlas (TCGA) database. We investigated the disease-free survival (DFS) rates of the high- and low-risk groups using the Kaplan-Meier method. Functional differences between the high- and low-risk groups were investigated by a gene set enrichment analysis (GSEA), and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The link between ferroptosis risk score and immune status was examined using CIBERSORT. The expression levels of core prognostic genes in benign prostatic hyperplasia (BPH) and PCa were verified using quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry (IHC).</p><p><strong>Results: </strong>A novel ferroptosis-related prognostic gene signature was established and tested in the Gene Expression Omnibus (GEO) database based on univariate and multivariate Cox regression analyses. Patients with PCa were classified into high- and low-risk groups based on this ferroptosis signature. Patients in the high-risk group had worse outcomes than those in the low-risk group. The predictive accuracy of the model was demonstrated by a receiver operating characteristic (ROC) analysis. An additional enrichment analysis of TCGA cohort revealed the immune-related pathways were significantly upregulated in the high-risk group, with areas under the curve (AUCs) of 0.85 at 1 year, 0.82 at 3 years, and 0.76 at 5 years. In the GEO cohort, the AUCs reached 0.69 at 1 year, 0.74 at 3 years, and 0.75 at 5 years. An additional enrichment analysis indicated a significant upregulation of cytokine-related pathways, immune receptor activity, and other immune-related pathways in the high-risk group. Furthermore, the analysis revealed that the proportions of mast cells and plasma cells were significantly lower in the high-risk group compared to the low-risk group of PCa patients. Conversely, the proportion of regulatory T cells (Tregs) was significantly higher in the high-risk group than in the low-risk group. According to the qRT-PCR, Western blot, and IHC results, DRD4, SRC, AKR1C2, and AIFM2 expression was significantly higher in PCa than BPH. We also showed that the ferrostatin 1-treated LNCaP cells had higher expression levels of DRD4, SRC, and AKR1C2.</p><p><strong>Conclusions: </strong>A prognostic signature of eight ferroptosis-related genes (FRGs) that may accurately predict PCa patient outcomes was constructed and validated. FRGs may contribute to anti-tumor immunity and s
{"title":"Ferroptosis-related gene signature predicts prognosis and immune microenvironment in prostate cancer.","authors":"Hao Wang, Dalang Fang, Jinxin Zhu, Lin Liu, Liang Xue, Liucheng Wang, Fatima Karzai, Emmanuel S Antonarakis, Fumihiko Urabe, Weiming Ma, Wanqing Wei","doi":"10.21037/tau-24-415","DOIUrl":"10.21037/tau-24-415","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis, an iron-dependent form of programmed cell death, significantly impacts cancer, yet its link to prostate cancer (PCa) prognosis remains underexplored. This study aims to develop and validate a ferroptosis-related gene signature to predict PCa prognosis and immune microenvironment differences, potentially identifying therapeutic targets.</p><p><strong>Methods: </strong>RNA-sequencing data of 478 PCa patients and corresponding clinical data were downloaded from The Cancer Genome Atlas (TCGA) database. We investigated the disease-free survival (DFS) rates of the high- and low-risk groups using the Kaplan-Meier method. Functional differences between the high- and low-risk groups were investigated by a gene set enrichment analysis (GSEA), and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The link between ferroptosis risk score and immune status was examined using CIBERSORT. The expression levels of core prognostic genes in benign prostatic hyperplasia (BPH) and PCa were verified using quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry (IHC).</p><p><strong>Results: </strong>A novel ferroptosis-related prognostic gene signature was established and tested in the Gene Expression Omnibus (GEO) database based on univariate and multivariate Cox regression analyses. Patients with PCa were classified into high- and low-risk groups based on this ferroptosis signature. Patients in the high-risk group had worse outcomes than those in the low-risk group. The predictive accuracy of the model was demonstrated by a receiver operating characteristic (ROC) analysis. An additional enrichment analysis of TCGA cohort revealed the immune-related pathways were significantly upregulated in the high-risk group, with areas under the curve (AUCs) of 0.85 at 1 year, 0.82 at 3 years, and 0.76 at 5 years. In the GEO cohort, the AUCs reached 0.69 at 1 year, 0.74 at 3 years, and 0.75 at 5 years. An additional enrichment analysis indicated a significant upregulation of cytokine-related pathways, immune receptor activity, and other immune-related pathways in the high-risk group. Furthermore, the analysis revealed that the proportions of mast cells and plasma cells were significantly lower in the high-risk group compared to the low-risk group of PCa patients. Conversely, the proportion of regulatory T cells (Tregs) was significantly higher in the high-risk group than in the low-risk group. According to the qRT-PCR, Western blot, and IHC results, DRD4, SRC, AKR1C2, and AIFM2 expression was significantly higher in PCa than BPH. We also showed that the ferrostatin 1-treated LNCaP cells had higher expression levels of DRD4, SRC, and AKR1C2.</p><p><strong>Conclusions: </strong>A prognostic signature of eight ferroptosis-related genes (FRGs) that may accurately predict PCa patient outcomes was constructed and validated. FRGs may contribute to anti-tumor immunity and s","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"2092-2109"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-30Epub Date: 2024-09-26DOI: 10.21037/tau-24-232
Guangzheng Li, Huanzhi Ding, Zhen Tian, Yuhua Huang, Yonggang Li, Nan Jiang, Ping Li
Background: Prostate cancer (PCa) as one of the most prevalent malignancies in men. We introduced a non-invasive quantitative measurement of intraprostatic fat content based on magnetic resonance proton density fat fraction (PDFF) imaging. The study aims to determine the fat fraction (FF) of PCa using proton density magnetic resonance imaging (MRI), gather clinical and routine MRI characteristics, and identify risk factors for high-risk PCa through multifactorial logistic regression.
Methods: Clinical and imaging data from 191 pathologically confirmed PCa patients were collected. Patients were stratified based on Gleason score (GS), with 63 in the intermediate- and low-risk group (GS =3+3, 3+4) and 128 in the high-risk group (GS ≥4+3). All patients underwent routine prostate MRI and FF imaging. Clinical and imaging data related to PCa were analyzed, including age, body mass index (BMI), prostate volume (PV) measured by MRI, smoking history, alcohol history, diabetes history, serum prostate-specific antigen (PSA) level, apparent diffusion coefficient (ADC) value, T2 signal intensity (T2SI), Prostate Imaging Reporting and Data System 2.1 (PI-RADS 2.1) score, GS, lesion FF, whole gland FF, periprostatic fat thickness (PPFT), and subcutaneous fat thickness (SFT). Independent risk factors for stratifying PCa risk were identified through multivariate logistic regression analysis, and a predictive model was established. Receiver operating characteristic (ROC) curve analysis was conducted for visual analysis.
Results: Significant differences were found in BMI, PV, PSA, tumor ADC value, standard T2SI, PI-RADS score, lesion FF, and PPFT between low- and medium-risk and high-risk groups (P<0.05). No significant differences were observed in age, smoking history, drinking history, diabetes history, and SFT between the two groups (P>0.05). GS correlated significantly with FF (ρ=0.6, P<0.001), PSA (ρ=0.432, P<0.001), ADC value (ρ=-0.379, P<0.001), and PI-RADS (ρ=0.366, P<0.001). Multiple logistic regression analysis revealed that an increase in FF, a PI-RADS score increase of 5 points, and a decrease in ADC value and PV were independent predictors of high-risk PCa (P<0.05). The ROC curve showed that the best cut-off value for the model was 0.67, with an area under the curve (AUC) of 0.907, sensitivity of 78.1%, and specificity of 88.9%.
Conclusions: The FF of PCa determined by proton density MRI is significantly associated with GS, serving as an independent predictor of high-risk PCa.
{"title":"Application of proton density fat fraction imaging in risk stratification of prostate cancer.","authors":"Guangzheng Li, Huanzhi Ding, Zhen Tian, Yuhua Huang, Yonggang Li, Nan Jiang, Ping Li","doi":"10.21037/tau-24-232","DOIUrl":"10.21037/tau-24-232","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) as one of the most prevalent malignancies in men. We introduced a non-invasive quantitative measurement of intraprostatic fat content based on magnetic resonance proton density fat fraction (PDFF) imaging. The study aims to determine the fat fraction (FF) of PCa using proton density magnetic resonance imaging (MRI), gather clinical and routine MRI characteristics, and identify risk factors for high-risk PCa through multifactorial logistic regression.</p><p><strong>Methods: </strong>Clinical and imaging data from 191 pathologically confirmed PCa patients were collected. Patients were stratified based on Gleason score (GS), with 63 in the intermediate- and low-risk group (GS =3+3, 3+4) and 128 in the high-risk group (GS ≥4+3). All patients underwent routine prostate MRI and FF imaging. Clinical and imaging data related to PCa were analyzed, including age, body mass index (BMI), prostate volume (PV) measured by MRI, smoking history, alcohol history, diabetes history, serum prostate-specific antigen (PSA) level, apparent diffusion coefficient (ADC) value, T2 signal intensity (T2SI), Prostate Imaging Reporting and Data System 2.1 (PI-RADS 2.1) score, GS, lesion FF, whole gland FF, periprostatic fat thickness (PPFT), and subcutaneous fat thickness (SFT). Independent risk factors for stratifying PCa risk were identified through multivariate logistic regression analysis, and a predictive model was established. Receiver operating characteristic (ROC) curve analysis was conducted for visual analysis.</p><p><strong>Results: </strong>Significant differences were found in BMI, PV, PSA, tumor ADC value, standard T2SI, PI-RADS score, lesion FF, and PPFT between low- and medium-risk and high-risk groups (P<0.05). No significant differences were observed in age, smoking history, drinking history, diabetes history, and SFT between the two groups (P>0.05). GS correlated significantly with FF (ρ=0.6, P<0.001), PSA (ρ=0.432, P<0.001), ADC value (ρ=-0.379, P<0.001), and PI-RADS (ρ=0.366, P<0.001). Multiple logistic regression analysis revealed that an increase in FF, a PI-RADS score increase of 5 points, and a decrease in ADC value and PV were independent predictors of high-risk PCa (P<0.05). The ROC curve showed that the best cut-off value for the model was 0.67, with an area under the curve (AUC) of 0.907, sensitivity of 78.1%, and specificity of 88.9%.</p><p><strong>Conclusions: </strong>The FF of PCa determined by proton density MRI is significantly associated with GS, serving as an independent predictor of high-risk PCa.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"1878-1890"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-30Epub Date: 2024-09-26DOI: 10.21037/tau-24-212
Sikui Shen, Xingpeng Di, Liyuan Xiang, Hong Li, Banghua Liao
Background: Renal stone is a highly prevalent life-long disease with a high recurrence rate. Chronic bowel diseases, including chronic gastrointestinal symptoms (chronic constipation or chronic diarrhea), are common gastrointestinal problems. We aimed to evaluate the associations of chronic constipation and chronic diarrhea with renal stones.
Methods: This large-scale, cross-sectional study was performed within participants (≥20 years old) from the National Health and Nutrition Examination Survey from 2007 to 2010. Logistic regression and sensitivity analyses were conducted to clarify the association between chronic bowel diseases and renal stones.
Results: A total of 8,067 participants aged ≥20 years were included. The prevalence of renal stones is 9.14%. Chronic diarrhea was positively related to the risk of renal stones [odds ratio (OR) =1.681, 95% confidence interval (CI): 1.212 to 2.330, P=0.004] after adjusting for all covariates. In participants with body mass index (BMI) over 30 kg/m2, chronic constipation was correlated with kidney stones in fully adjusted model 2 (OR =2.142, 95% CI: 1.389 to 3.303, P=0.004).
Conclusions: Our findings provide evidence that chronic diarrhea is associated with an increased risk of renal stones. Chronic constipation is positively related to the risk of renal stones in participants with BMI over 30 kg/m2. Health care should focus more on bowel health status for the prevention of related diseases. More prospective cohort studies are needed.
{"title":"Association of chronic constipation and chronic diarrhea with renal stones: a cross-sectional study of the National Health and Nutrition Examination Survey 2007-2010.","authors":"Sikui Shen, Xingpeng Di, Liyuan Xiang, Hong Li, Banghua Liao","doi":"10.21037/tau-24-212","DOIUrl":"10.21037/tau-24-212","url":null,"abstract":"<p><strong>Background: </strong>Renal stone is a highly prevalent life-long disease with a high recurrence rate. Chronic bowel diseases, including chronic gastrointestinal symptoms (chronic constipation or chronic diarrhea), are common gastrointestinal problems. We aimed to evaluate the associations of chronic constipation and chronic diarrhea with renal stones.</p><p><strong>Methods: </strong>This large-scale, cross-sectional study was performed within participants (≥20 years old) from the National Health and Nutrition Examination Survey from 2007 to 2010. Logistic regression and sensitivity analyses were conducted to clarify the association between chronic bowel diseases and renal stones.</p><p><strong>Results: </strong>A total of 8,067 participants aged ≥20 years were included. The prevalence of renal stones is 9.14%. Chronic diarrhea was positively related to the risk of renal stones [odds ratio (OR) =1.681, 95% confidence interval (CI): 1.212 to 2.330, P=0.004] after adjusting for all covariates. In participants with body mass index (BMI) over 30 kg/m<sup>2</sup>, chronic constipation was correlated with kidney stones in fully adjusted model 2 (OR =2.142, 95% CI: 1.389 to 3.303, P=0.004).</p><p><strong>Conclusions: </strong>Our findings provide evidence that chronic diarrhea is associated with an increased risk of renal stones. Chronic constipation is positively related to the risk of renal stones in participants with BMI over 30 kg/m<sup>2</sup>. Health care should focus more on bowel health status for the prevention of related diseases. More prospective cohort studies are needed.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"2036-2044"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Low-intensity pulsed ultrasound (LIPUS) is an effective and safe treatment for mild to moderate erectile dysfunction (ED). This study aimed to investigate the efficacy and safety of combining LIPUS with tadalafil in treating severe ED.
Methods: The data from 27 patients treated with LIPUS alone (group A) and 21 patients treated with a combination of LIPUS and daily 10 mg tadalafil (group B) were retrospectively analyzed. The LIPUS regimen consisted of twice-weekly treatments for 4 consecutive weeks. The treatment was considered effective if the change in International Index of Erectile Function-Erectile Function Domain (IIEF-EF) score after treatment was greater than or equal to the minimal clinically important difference (MCID) (the MCID for severe ED is 7 points). The effectiveness, IIEF-EF score, erectile hardness score (EHS), peak systolic velocity (PSV), end diastolic velocity (EDV), and adverse events were evaluated before treatment, 4 weeks after treatment, and 12 weeks after treatment.
Results: Compared to pre-treatment, both groups showed significant improvement in IIEF-EF score and EHS at 4 and 12 weeks after treatment (P<0.001), with no statistically significant difference between the two time points (P>0.05). The effective rate did not significantly differ between group A (9/27, 33.3%) and group B (10/21, 47.62%) at 4 weeks or between group A (9/27, 33.3%) and group B (12/21, 57.14%) at 12 weeks after treatment (P=0.32, P=0.10). However, in patients without comorbidities, the effective rate of group B (12/18, 66.67%) was higher than that of group A (9/25, 36.00%) at 12 weeks after treatment (P=0.047). After LIPUS treatment, the PSV level significantly increased and the EDV level significantly decreased compared with before treatment (P<0.05). No adverse events were reported.
Conclusions: The study suggests that LIPUS has a therapeutic effect on severe ED patients, especially those without comorbidities. It may have a synergistic or overlapping effect with phosphodiesterase type 5 inhibitors (PDE5Is) on severe ED patients without comorbidities.
背景：低强度脉冲超声（LIPUS）是治疗轻度至中度勃起功能障碍（ED）的一种有效而安全的方法。本研究旨在探讨 LIPUS 与他达拉非联合治疗重度 ED 的有效性和安全性：回顾性分析了27例单独使用LIPUS治疗的患者（A组）和21例联合使用LIPUS和每日10毫克他达拉非治疗的患者（B组）的数据。LIPUS 治疗方案包括连续 4 周、每周两次的治疗。如果治疗后国际勃起功能指数-勃起功能领域（IIEF-EF）评分的变化大于或等于最小临床重要差异（MCID）（重度ED的MCID为7分），则认为治疗有效。对治疗前、治疗后4周和治疗后12周的疗效、IIEF-EF评分、勃起硬度评分（EHS）、收缩峰值速度（PSV）、舒张末期速度（EDV）和不良反应进行了评估：与治疗前相比，两组患者在治疗后 4 周和 12 周的 IIEF-EF 评分和 EHS 均有显著改善（P0.05）。治疗 4 周后，A 组（9/27，33.3%）和 B 组（10/21，47.62%）的有效率无明显差异，治疗 12 周后，A 组（9/27，33.3%）和 B 组（12/21，57.14%）的有效率也无明显差异（P=0.32，P=0.10）。然而，在无合并症的患者中，B 组（12/18，66.67%）在治疗后 12 周的有效率高于 A 组（9/25，36.00%）（P=0.047）。与治疗前相比，LIPUS 治疗后 PSV 水平明显升高，EDV 水平明显下降（PConclusions：该研究表明，LIPUS 对重度 ED 患者，尤其是无合并症的患者有治疗作用。它与5型磷酸二酯酶抑制剂（PDE5Is）对无合并症的重度ED患者可能具有协同或重叠作用。
{"title":"Efficacy and safety of low-intensity pulsed ultrasound (LIPUS) combined with tadalafil in the treatment of severe erectile dysfunction: a retrospective cohort study.","authors":"Qing-Qiang Gao, Jing Wang, Da-Sheng Li, Yu-Tian Dai, Zhi-Ran Li, Xiao-Zhi Zhao","doi":"10.21037/tau-24-154","DOIUrl":"10.21037/tau-24-154","url":null,"abstract":"<p><strong>Background: </strong>Low-intensity pulsed ultrasound (LIPUS) is an effective and safe treatment for mild to moderate erectile dysfunction (ED). This study aimed to investigate the efficacy and safety of combining LIPUS with tadalafil in treating severe ED.</p><p><strong>Methods: </strong>The data from 27 patients treated with LIPUS alone (group A) and 21 patients treated with a combination of LIPUS and daily 10 mg tadalafil (group B) were retrospectively analyzed. The LIPUS regimen consisted of twice-weekly treatments for 4 consecutive weeks. The treatment was considered effective if the change in International Index of Erectile Function-Erectile Function Domain (IIEF-EF) score after treatment was greater than or equal to the minimal clinically important difference (MCID) (the MCID for severe ED is 7 points). The effectiveness, IIEF-EF score, erectile hardness score (EHS), peak systolic velocity (PSV), end diastolic velocity (EDV), and adverse events were evaluated before treatment, 4 weeks after treatment, and 12 weeks after treatment.</p><p><strong>Results: </strong>Compared to pre-treatment, both groups showed significant improvement in IIEF-EF score and EHS at 4 and 12 weeks after treatment (P<0.001), with no statistically significant difference between the two time points (P>0.05). The effective rate did not significantly differ between group A (9/27, 33.3%) and group B (10/21, 47.62%) at 4 weeks or between group A (9/27, 33.3%) and group B (12/21, 57.14%) at 12 weeks after treatment (P=0.32, P=0.10). However, in patients without comorbidities, the effective rate of group B (12/18, 66.67%) was higher than that of group A (9/25, 36.00%) at 12 weeks after treatment (P=0.047). After LIPUS treatment, the PSV level significantly increased and the EDV level significantly decreased compared with before treatment (P<0.05). No adverse events were reported.</p><p><strong>Conclusions: </strong>The study suggests that LIPUS has a therapeutic effect on severe ED patients, especially those without comorbidities. It may have a synergistic or overlapping effect with phosphodiesterase type 5 inhibitors (PDE5Is) on severe ED patients without comorbidities.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"2045-2054"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-30Epub Date: 2024-09-24DOI: 10.21037/tau-24-356
Ram A Pathak, Ashok K Hemal
{"title":"Preface to \"newer techniques and tools lead to a paradigm shift in the diagnosis and management of upper tract urothelial carcinoma\".","authors":"Ram A Pathak, Ashok K Hemal","doi":"10.21037/tau-24-356","DOIUrl":"https://doi.org/10.21037/tau-24-356","url":null,"abstract":"","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"1773-1774"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-30Epub Date: 2024-09-26DOI: 10.21037/tau-24-190
Jiahao Jiang, Fei Xiao, Lanxin Yang, Yan Zeng, Jing Chen, Hengcheng Zhu, Lingqi Liu
Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common male urological disease characterized by chronic pelvic pain and various discomforts. Astaxanthin (AST) has multiple functions, including anti-inflammatory property, but it is unclear whether AST plays a key role in CP/CPPS and how it works. This study aimed to investigate the protective effect of AST on CP/CPPS in rats and the underlying mechanism.
Methods: A CP/CPPS rat model was induced by intraprostatic injection of carrageenan and the blood specimens and prostates were harvested for further research after oral administration of AST for 4 weeks.
Results: Tactile allodynia test showed that AST ameliorated chronic pelvic pain in a dose-depended manner. In addition, histological evaluation indicated that AST alleviated CP/CPPS rat prostate histological inflammation. Meanwhile, AST suppressed the expression of proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6, IL-8, and tumor necrosis factor-α (TNF-α). Besides, AST inhibited the activities of prostaglandin E2 (PGE2) and cyclooxygenase 2 (COX2). Furthermore, AST decreased the activation of the nuclear factor-κB (NF-κB) signaling pathway.
Conclusions: Our study has shown that AST exerts an anti-inflammatory and protective effect against CP/CPPS and the function is mediated at least through the suppression of NF-κB signaling pathway. These results provide evidence of AST as the potential agents for the treatment of CP/CPPS.
{"title":"Protective effect of astaxanthin on chronic prostatitis/chronic pelvic pain syndrome in rat through modulating NF-κB signaling pathway.","authors":"Jiahao Jiang, Fei Xiao, Lanxin Yang, Yan Zeng, Jing Chen, Hengcheng Zhu, Lingqi Liu","doi":"10.21037/tau-24-190","DOIUrl":"10.21037/tau-24-190","url":null,"abstract":"<p><strong>Background: </strong>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common male urological disease characterized by chronic pelvic pain and various discomforts. Astaxanthin (AST) has multiple functions, including anti-inflammatory property, but it is unclear whether AST plays a key role in CP/CPPS and how it works. This study aimed to investigate the protective effect of AST on CP/CPPS in rats and the underlying mechanism.</p><p><strong>Methods: </strong>A CP/CPPS rat model was induced by intraprostatic injection of carrageenan and the blood specimens and prostates were harvested for further research after oral administration of AST for 4 weeks.</p><p><strong>Results: </strong>Tactile allodynia test showed that AST ameliorated chronic pelvic pain in a dose-depended manner. In addition, histological evaluation indicated that AST alleviated CP/CPPS rat prostate histological inflammation. Meanwhile, AST suppressed the expression of proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6, IL-8, and tumor necrosis factor-α (TNF-α). Besides, AST inhibited the activities of prostaglandin E2 (PGE2) and cyclooxygenase 2 (COX2). Furthermore, AST decreased the activation of the nuclear factor-κB (NF-κB) signaling pathway.</p><p><strong>Conclusions: </strong>Our study has shown that AST exerts an anti-inflammatory and protective effect against CP/CPPS and the function is mediated at least through the suppression of NF-κB signaling pathway. These results provide evidence of AST as the potential agents for the treatment of CP/CPPS.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"1971-1983"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Ectopic renal hydronephrosis is a relatively rare condition, with literature primarily consisting of scattered case studies. The ectopic kidney poses technical challenges to surgeons due to its structural and anatomical abnormalities. This study aims to share our initial experiences with minimally invasive pyeloplasty as a management approach for ectopic renal hydronephrosis in adult patients.
Case description: Between August 2018 and January 2023, six patients underwent minimally invasive pyeloplasty for ectopic kidneys. The patient cohort consisted of four individuals with pelvic kidneys, one with an iliac kidney, and one with an abdominal kidney. Among these, three cases were left-sided, two were right-sided, and one was isolated. The median patient age was 27 (range, 18-45) years. Four patients underwent robot-assisted laparoscopic pyeloplasty, while two underwent laparoscopic pyeloplasty. The median operative time was 134 (range, 63-240) minutes. After a median follow-up duration of 28.5 (range, 6-59) months, two patients required nephrectomy, with vesicoureteral reflux (VUR) and malrotation potentially contributing to surgical failure in these cases. The remaining four patients showed either stable or improved hydronephrosis and renal function. The overall operative success rate was 66.7%.
Conclusions: The rarity and anatomical variations of ectopic kidneys hinder the standardization of surgical approaches. The integration of three-dimensional (3D) virtual reconstruction and tailored surgical techniques contributes to enhanced outcomes in ectopic renal hydronephrosis cases. Furthermore, continued research and refinement of surgical approaches are needed.
{"title":"Pyeloplasty for the treatment of ectopic renal hydronephrosis in adults: a case series of six patients.","authors":"Wencong Han, Zhihua Li, Guanpeng Han, Liqing Xu, Xinfei Li, Shubo Fan, Bing Wang, Chen Huang, Yuanshan Cui, Zheng Zhang, Liqun Zhou, Kunlin Yang, Xuesong Li","doi":"10.21037/tau-24-142","DOIUrl":"10.21037/tau-24-142","url":null,"abstract":"<p><strong>Background: </strong>Ectopic renal hydronephrosis is a relatively rare condition, with literature primarily consisting of scattered case studies. The ectopic kidney poses technical challenges to surgeons due to its structural and anatomical abnormalities. This study aims to share our initial experiences with minimally invasive pyeloplasty as a management approach for ectopic renal hydronephrosis in adult patients.</p><p><strong>Case description: </strong>Between August 2018 and January 2023, six patients underwent minimally invasive pyeloplasty for ectopic kidneys. The patient cohort consisted of four individuals with pelvic kidneys, one with an iliac kidney, and one with an abdominal kidney. Among these, three cases were left-sided, two were right-sided, and one was isolated. The median patient age was 27 (range, 18-45) years. Four patients underwent robot-assisted laparoscopic pyeloplasty, while two underwent laparoscopic pyeloplasty. The median operative time was 134 (range, 63-240) minutes. After a median follow-up duration of 28.5 (range, 6-59) months, two patients required nephrectomy, with vesicoureteral reflux (VUR) and malrotation potentially contributing to surgical failure in these cases. The remaining four patients showed either stable or improved hydronephrosis and renal function. The overall operative success rate was 66.7%.</p><p><strong>Conclusions: </strong>The rarity and anatomical variations of ectopic kidneys hinder the standardization of surgical approaches. The integration of three-dimensional (3D) virtual reconstruction and tailored surgical techniques contributes to enhanced outcomes in ectopic renal hydronephrosis cases. Furthermore, continued research and refinement of surgical approaches are needed.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"2110-2118"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: In recent years, prostatic artery embolization (PAE) has gradually become a hot topic in the treatment of symptomatic benign prostatic hyperplasia (BPH). However, there is an ongoing debate regarding the best embolization material for PAE. This study aimed to compare the safety and efficacy of the temperature-sensitive liquid embolic agent (TempSLE) combined with polyvinyl alcohol (PVA) microspheres and simple PVA microspheres for PAE in treating lower urinary tract symptoms (LUTS) caused by BPH.
Methods: The clinical data of 39 patients with LUTS caused by BPH were included in this study, including 21 cases of PVA microspheres group and 18 cases of PVA microspheres + TempSLE group. The changes in various subjective and objective indexes were compared between the two groups before PAE, 1 and 3 months after operation.
Results: Three months after operation, the improvement in prostate volume (PV), post-void residual volume (PVR), peak urinary flow rate (Qmax), international prostate symptom score (IPSS), quality of life (QoL) and total prostate-specific antigen (T-PSA) in both groups were significantly improved compared with those before operation (P<0.05). And the above clinical improvement indicators at the 3-month mark demonstrated a statistically significant difference between the two groups (P<0.05). Compared with the PVA microspheres group, the prostate necrosis rate of the PVA microspheres + TempSLE was higher at 1 and 3 months after operation (P<0.05). Moreover, the PVA microspheres + TempSLE group had no significant complications, with the exception of a single case of transient gross hematuria during the perioperative period.
Conclusions: The combination of PVA microspheres and TempSLE for PAE appears to be safe and effective in the treatment of symptomatic BPH patients, with a higher degree of damage to hyperplastic prostate tissue compared to simple PVA microspheres embolization.
{"title":"Retrospective observation of the early efficacy and safety of temperature-sensitive liquid embolic agent combined with polyvinyl alcohol microspheres for prostatic artery embolization in the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia.","authors":"Fangfang Lin, Qian Chen, Meizhu Gao, Yuanyuan Ji, Dandan Ruan, Jianhui Zhang, Yanfeng Zhou, Shaojie Wu, Senlin Cai, Jiewei Luo, Zhuting Fang, Yi Tang","doi":"10.21037/tau-24-215","DOIUrl":"10.21037/tau-24-215","url":null,"abstract":"<p><strong>Background: </strong>In recent years, prostatic artery embolization (PAE) has gradually become a hot topic in the treatment of symptomatic benign prostatic hyperplasia (BPH). However, there is an ongoing debate regarding the best embolization material for PAE. This study aimed to compare the safety and efficacy of the temperature-sensitive liquid embolic agent (TempSLE) combined with polyvinyl alcohol (PVA) microspheres and simple PVA microspheres for PAE in treating lower urinary tract symptoms (LUTS) caused by BPH.</p><p><strong>Methods: </strong>The clinical data of 39 patients with LUTS caused by BPH were included in this study, including 21 cases of PVA microspheres group and 18 cases of PVA microspheres + TempSLE group. The changes in various subjective and objective indexes were compared between the two groups before PAE, 1 and 3 months after operation.</p><p><strong>Results: </strong>Three months after operation, the improvement in prostate volume (PV), post-void residual volume (PVR), peak urinary flow rate (Q<sub>max</sub>), international prostate symptom score (IPSS), quality of life (QoL) and total prostate-specific antigen (T-PSA) in both groups were significantly improved compared with those before operation (P<0.05). And the above clinical improvement indicators at the 3-month mark demonstrated a statistically significant difference between the two groups (P<0.05). Compared with the PVA microspheres group, the prostate necrosis rate of the PVA microspheres + TempSLE was higher at 1 and 3 months after operation (P<0.05). Moreover, the PVA microspheres + TempSLE group had no significant complications, with the exception of a single case of transient gross hematuria during the perioperative period.</p><p><strong>Conclusions: </strong>The combination of PVA microspheres and TempSLE for PAE appears to be safe and effective in the treatment of symptomatic BPH patients, with a higher degree of damage to hyperplastic prostate tissue compared to simple PVA microspheres embolization.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"1847-1858"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-30Epub Date: 2024-09-26DOI: 10.21037/tau-24-268
Chuanfeng Liu, Haifang Guan, Shouxia Cao, Yongqiang Xia, Fuming Wang
Background: With the aging population, patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) often face multiple chronic conditions (multimorbidity), significantly impacting their quality of life. This study aims to determine the relationship between LUTS/BPH, multimorbidity, and various chronic diseases in middle-aged and elderly Chinese populations.
Methods: This cross-sectional study utilizes data from the China Health and Retirement Longitudinal Study (CHARLS), involving 6,645 residents aged 45 and above. Data on 14 chronic diseases were collected, with multimorbidity defined based on the presence of 2-5 chronic conditions. The number of chronic conditions was further categorized into five groups. Propensity score matching (PSM) was used to control for 11 confounding factors. Linear regression was employed to analyze the relationship between LUTS/BPH and the number of chronic conditions in middle-aged and elderly Chinese men before and after PSM. Both univariate and multivariate logistic regression analyses were used to explore the association between LUTS/BPH and multimorbidity as well as each chronic disease.
Results: The prevalence of multimorbidity was significantly higher among middle-aged and elderly individuals with LUTS/BPH compared to those without. Before PSM, LUTS/BPH was positively correlated with the number of chronic diseases (β=0.175, P<0.001), and the risk of multimorbidity significantly increased, showing a dose-response relationship. The risk of having at least two chronic diseases in patients with LUTS/BPH was 2.39 times higher than in those without LUTS/BPH [odds ratio (OR) =2.39, 95% confidence interval (CI): 2.04-2.80], and the risk of having five chronic diseases was 3.97 times higher (OR =3.97, 95% CI: 3.14-4.99). After PSM, 819 pairs were successfully matched. The positive correlation between LUTS/BPH and multimorbidity still existed, with the risks of having at least two and five chronic diseases being 2.37 times (OR =2.37, 95% CI: 1.94-2.90) and 3.69 times (OR =3.69, 95% CI: 2.62-5.29) higher, respectively. Among them, the risk of emotional/nervous/psychiatric problems was the highest in LUTS/BPH patients (OR =6.58, 95% CI: 2.22-28.13), while the risk of arthritis/rheumatism was the lowest (OR =1.60, 95% CI: 1.30-1.98).
Conclusions: In the Chinese population, LUTS/BPH is closely associated with multimorbidity and each of the 14 chronic diseases examined, with a dose-response relationship based on the number of chronic diseases defined within multimorbidity. It is imperative to incorporate LUTS/BPH into multimorbidity research and management. We recommend that clinicians and policymakers consider the increased risk of multimorbidity and various chronic diseases among male LUTS/BPH patients.
{"title":"The association between lower urinary tract symptoms secondary to benign prostatic hyperplasia and multimorbidity among Chinese middle-aged and elderly males: evidence based on propensity score matching.","authors":"Chuanfeng Liu, Haifang Guan, Shouxia Cao, Yongqiang Xia, Fuming Wang","doi":"10.21037/tau-24-268","DOIUrl":"10.21037/tau-24-268","url":null,"abstract":"<p><strong>Background: </strong>With the aging population, patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) often face multiple chronic conditions (multimorbidity), significantly impacting their quality of life. This study aims to determine the relationship between LUTS/BPH, multimorbidity, and various chronic diseases in middle-aged and elderly Chinese populations.</p><p><strong>Methods: </strong>This cross-sectional study utilizes data from the China Health and Retirement Longitudinal Study (CHARLS), involving 6,645 residents aged 45 and above. Data on 14 chronic diseases were collected, with multimorbidity defined based on the presence of 2-5 chronic conditions. The number of chronic conditions was further categorized into five groups. Propensity score matching (PSM) was used to control for 11 confounding factors. Linear regression was employed to analyze the relationship between LUTS/BPH and the number of chronic conditions in middle-aged and elderly Chinese men before and after PSM. Both univariate and multivariate logistic regression analyses were used to explore the association between LUTS/BPH and multimorbidity as well as each chronic disease.</p><p><strong>Results: </strong>The prevalence of multimorbidity was significantly higher among middle-aged and elderly individuals with LUTS/BPH compared to those without. Before PSM, LUTS/BPH was positively correlated with the number of chronic diseases (β=0.175, P<0.001), and the risk of multimorbidity significantly increased, showing a dose-response relationship. The risk of having at least two chronic diseases in patients with LUTS/BPH was 2.39 times higher than in those without LUTS/BPH [odds ratio (OR) =2.39, 95% confidence interval (CI): 2.04-2.80], and the risk of having five chronic diseases was 3.97 times higher (OR =3.97, 95% CI: 3.14-4.99). After PSM, 819 pairs were successfully matched. The positive correlation between LUTS/BPH and multimorbidity still existed, with the risks of having at least two and five chronic diseases being 2.37 times (OR =2.37, 95% CI: 1.94-2.90) and 3.69 times (OR =3.69, 95% CI: 2.62-5.29) higher, respectively. Among them, the risk of emotional/nervous/psychiatric problems was the highest in LUTS/BPH patients (OR =6.58, 95% CI: 2.22-28.13), while the risk of arthritis/rheumatism was the lowest (OR =1.60, 95% CI: 1.30-1.98).</p><p><strong>Conclusions: </strong>In the Chinese population, LUTS/BPH is closely associated with multimorbidity and each of the 14 chronic diseases examined, with a dose-response relationship based on the number of chronic diseases defined within multimorbidity. It is imperative to incorporate LUTS/BPH into multimorbidity research and management. We recommend that clinicians and policymakers consider the increased risk of multimorbidity and various chronic diseases among male LUTS/BPH patients.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"1932-1945"},"PeriodicalIF":1.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号